UBS Group’s Entellus Medical, Inc. Common Stock ENTL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-3,035
| Closed | -$74K | – | 8505 |
|
|
2017
Q4 | $74K | Buy |
3,035
+2,129
| +235% | +$40.9K | ﹤0.01% | 5570 |
|
|
2017
Q3 | $16K | Sell |
906
-3,694
| -80% | -$64K | ﹤0.01% | 6629 |
|
|
2017
Q2 | $76K | Buy |
4,600
+2,782
| +153% | +$38.7K | ﹤0.01% | 5362 |
|
|
2017
Q1 | $25K | Buy |
1,818
+84
| +5% | +$1.35K | ﹤0.01% | 6005 |
|
|
2016
Q4 | $33K | Buy |
1,734
+506
| +41% | +$9.71K | ﹤0.01% | 6175 |
|
|
2016
Q3 | $27K | Buy |
1,228
+628
| +105% | +$11.8K | ﹤0.01% | 6054 |
|
|
2016
Q2 | $11K | Sell |
600
-425
| -41% | -$7.32K | ﹤0.01% | 6749 |
|
|
2016
Q1 | $19K | Sell |
1,025
-75
| -7% | -$1.21K | ﹤0.01% | 6265 |
|
|
2015
Q4 | $19K | Hold |
1,100
| – | – | ﹤0.01% | 6833 |
|
|
2015
Q3 | $20K | Hold |
1,100
| – | – | ﹤0.01% | 6715 |
|
|
2015
Q2 | $28K | Buy |
1,100
+600
| +120% | +$15.2K | ﹤0.01% | 6573 |
|
|
2015
Q1 | $11K | Buy |
+500
| New | +$10.8K | ﹤0.01% | 7598 |
|
UBS Group's ENTL Position: Q1 2018 in Review
UBS Group sold out of Entellus Medical, Inc. Common Stock (ENTL) in Q1 2018, closing a stake of 3,035 shares — an estimated $74K sold.
UBS Group first reported a position in ENTL in Q1 2015 and held it in 12 quarters. The position peaked at $76K in Q2 2017. 0 funds tracked by Wall St. Rank hold ENTL as of Q1 2018.
- UBS Group reported no remaining Entellus Medical, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
- UBS Group sold 3,035 Entellus Medical, Inc. Common Stock shares in Q1 2018, an estimated $74K.
- UBS Group first reported a position in Entellus Medical, Inc. Common Stock in Q1 2015 and held it in 12 quarters.
- UBS Group's Entellus Medical, Inc. Common Stock position peaked at $76K in Q2 2017.
- 0 funds tracked by Wall St. Rank held Entellus Medical, Inc. Common Stock as of Q1 2018.
Based on UBS Group's 13F filing for Q1 2018, filed 15 May 2018.